Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.58 |
| ▸ | NOS1 | P29475 | 5/20 | 0.58 |
| ▸ | NOS3 | P29474 | 4/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527409 | 1.00 | NOS2 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL881063 | 1.00 | NOS2 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL15091324 | 0.98 | NOS2 (0.56) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL920513 | 0.98 | NOS2 (0.56) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL15091326 | 0.98 | NOS2 (0.56) | NOS2NOS1NOS3GSRARG2 | |
| Acetic Acid SCHEMBL919118 | 0.96 | NOS2 (0.54) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL1527395 | 0.94 | NOS2 (0.65) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL1527394 | 0.94 | NOS2 (0.65) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL25629375 | 0.94 | NOS2 (0.65) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL8127399 | 0.92 | NOS2 (0.62) | NOS2NOS1NOS3GSRARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745237-A1 | RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF | YUN HO BIO CO., LTD (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2026100273-A1 | METHOD FOR PRODUCING USEFUL SUBSTANCE, CULTURE SOLUTION FOR CULTURING ALGAE, APPARATUS FOR PRODUCING USEFUL SUBSTANCE, AND ALGAE CONTAINING USEFUL SUBSTANCE | ＮＴＴ株式会社 | 2026-05-15 | — | — | WO | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20250332223-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | UNIV MIAMI (US) | 2025-10-30 | — | — | US | claimed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | claimed |
| US-12377135-B2 | GHRH antagonists for use in a method of treating sarcoidosis | UNIVERSITY OF MIAMI (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025147774-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING AND TREATMENT OF CANCER AND OTHER DISORDERS | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-17 | — | — | WO | claimed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | claimed |
| EP-3999095-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2022-05-25 | — | — | EP | claimed |
| US-20220143149-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-05-12 | — | — | US | claimed |
| WO-2022067052-A1 | PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE | ELANCO US INC. (US) | 2022-03-31 | — | — | WO | claimed |
| CN-113892029-A | Mass spectrometry method for detecting metabolites | 梅塔博隆股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | claimed |
| US-7893048-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | claimed |
| EP-1896410-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| WO-2006137796-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | NOS2 3625/4885NOS1 4062/4885NOS3 4202/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | NOS2 3478/4885NOS1 3994/4885NOS3 3534/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | NOS2 1516/4885NOS1 1882/4885NOS3 1690/4885 |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | NOS2 3352/4885NOS1 4173/4885NOS3 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.